|Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer|
F Di Nicolantonio, M Martini, F Molinari, A Sartore Bianchi, S Arena, ...
|Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab|
W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ...
Jama 304 (16), 1812-1820, 2010
|Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus|
F Di Nicolantonio, S Arena, J Tabernero, S Grosso, F Molinari, ...
The Journal of clinical investigation 120 (8), 2858-2866, 2010
|Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer|
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
|Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer|
S Arena, B Bellosillo, G Siravegna, A Martínez, I Cañadas, L Lazzari, ...
Clinical cancer research 21 (9), 2157-2166, 2015
|Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells|
H Konishi, M Mohseni, A Tamaki, JP Garay, S Croessmann, S Karnan, ...
Proceedings of the National Academy of Sciences 108 (43), 17773-17778, 2011
|Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET|
C Basilico, S Pennacchietti, E Vigna, C Chiriaco, S Arena, A Bardelli, ...
Clinical Cancer Research 19 (9), 2381-2392, 2013
|Genetic analysis of the kinome and phosphatome in cancer|
S Arena, S Benvenuti, A Bardelli
Cellular and Molecular Life Sciences CMLS 62 (18), 2092-2099, 2005
|PIK3CA cancer mutations display gender and tissue specificity patterns|
S Benvenuti, M Frattini, S Arena, C Zanon, V Cappelletti, D Coradini, ...
Human mutation 29 (2), 284-288, 2008
|Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses|
F Di Nicolantonio, S Arena, M Gallicchio, D Zecchin, M Martini, SE Flonta, ...
Proceedings of the National Academy of Sciences 105 (52), 20864-20869, 2008
|Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer|
BO Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G Corti, ...
Nature communications 7, 13665, 2016
|Expression and functional regulation of myoglobin in epithelial cancers|
SE Flonta, S Arena, A Pisacane, P Michieli, A Bardelli
The American journal of pathology 175 (1), 201-206, 2009
|MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations|
S Arena, G Siravegna, B Mussolin, JD Kearns, BB Wolf, S Misale, ...
Science translational medicine 8 (324), 324ra14-324ra14, 2016
|Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer|
D Oddo, EM Sennott, L Barault, E Valtorta, S Arena, A Cassingena, ...
Cancer research 76 (15), 4504-4515, 2016
|p21 (WAF1/CIP1) Mediates the Growth Response to TGF-b in Human Epithelial Cells|
KE Bachman, BG Blair, K Brenner, A Bardelli, S Arena, S Zhou, J Hicks, ...
Cancer biology & therapy 3 (2), 221-225, 2004
|Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes|
JJ Wallin, J Guan, KA Edgar, W Zhou, R Francis, AC Torres, PM Haverty, ...
PloS one 7 (5), e36402, 2012
|Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells|
F Saletta, G Matullo, M Manuguerra, S Arena, A Bardelli, P Vineis
cancer research 67 (15), 7088-7094, 2007
|The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer|
FJ Sanchez-Martín, B Bellosillo, M Gelabert-Baldrich, A Dalmases, ...
Clinical Cancer Research 22 (13), 3260-3267, 2016
|Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic …|
A Sartore-Bianchi, K Bencardino, F Di Nicolantonio, F Pozzi, C Funaioli, ...
Targeted oncology 5 (1), 19-28, 2010
|Genetic targeting of the kinase activity of the Met receptor in cancer cells|
S Arena, A Pisacane, M Mazzone, PM Comoglio, A Bardelli
Proceedings of the National Academy of Sciences 104 (27), 11412-11417, 2007